A fixed-duration regimen of AstraZeneca’s Calquence (acalabrutinib) in combination with venetoclax, with or without obinutuzumab, has ...
Addex Therapeutics a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neu...
IgA nephropathy (IgAN) is an autoimmune disorder that affects the kidneys by impairing the filtration function of the small blood vessels. It is caused by ...
Purchase price of $47 per share in cash represents an enterprise value of €3.0 billion ($3.4 billion), or an equity value of approximately $...
Debiopharm Research & Manufacturing S.A. (Debiopharm, www.debiopharm.com), a Swiss-based global biopharmaceutical company aiming to cure cancer an...
Jazz Pharmaceuticals plc announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adop...
Argent BioPharma Ltd. , a clinical-stage biopharmaceutical company specializing in neuroimmune therapies, is pleased to announce its official entry into th...
Boehringer Ingelheim and Tessellate Bio, a precision oncology company with a focus on developing novel synthetic lethality approaches, have entered into ...
Animal-free, high-yield solutions for scalable production Strategic partnership accelerating innovation from lab to GMP scale Breakthrough media for ...
Eisai Co., Ltd. and Biogen Inc. announced that the European Commission (EC) has granted marketing authorization (MA) for Leqembi® (lecanemab), a m...
Partnership with specialist life science distributor establishes sales channel in high-demand market and strengthens global network Hypothermic pres...
In the European Union (EU), lecanemab is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment and mild de...
A new, mid-size Contract Development Manufacturing Organisation (CDMO), Meribel Pharma Solutions has launched today with an extensive integrated network ...
Partnership bolsters Boehringer’s autoimmune and inflammatory disease pipeline portfolio aiming to tackle areas of high unmet patient need. The ...
© 2025 Biopharma Boardroom. All Rights Reserved.